Trial Profile
A study of biomarker predicting the effect of Nivolumab for unresectable advanced or recurrent gastric cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Biomarker; Therapeutic Use
- 03 Jul 2020 Results published in the British Journal of Cancer.
- 27 Feb 2020 Status changed to completed.
- 25 Jan 2020 Results (n=138) assessing ral-world efficacy of nivolumab in previously treated gastric cancer patients, presented at the 2020 Gastrointestinal Cancers Symposium.